Synchronous or metachronous occurrences of both prostate cancer and male breast cancer are rarely reported, but provide insight into their hormonal and genetic biology. We sought to determine the incidence of prostate cancer in male breast cancer patients at our institution, and to examine estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu receptor (HR) status in these patients. A retrospective review was conducted of male breast cancer patients from 1990 to 2006. Histopathologic characteristics and hormone receptor expression was obtained. In 69 patients with male breast cancer, 12 (17%) also had a diagnosis of prostate cancer. Nine had ER-positive status and three were unreported. PR status was positive in 5, whereas 3 had PR-negative status. HR status was positive in 1, whereas 5 had HR-negative status. Male breast cancer patients in this cohort have an incidence of prostate cancer higher than would be predicted in the general population; this risk factor has implications for careful prostate cancer screening.
Introduction
Although prostate cancer remains the most common non-cutaneous malignancy in men, breast cancer in men is rare. In 2002, an estimated 1500 new cases of male breast cancer occurred, which comprised less than 1% of all breast cancer cases in the United States.
1,2 The incidence of male breast cancer has remained stable, in contrast to the rising incidence in women. 3 The prevalence of male breast cancer increases with age; the average age at diagnosis is 60 years old, which is 10 years greater than in women. 4 The incidence of breast cancer in men varies considerably by geographic location. In Uganda and Zambia, the annual incidence rates are 5 and 15%, respectively. 5, 6 These relatively higher rates are correlated with endemic infectious diseases causing liver damage, leading to hyperestrogenism. 7 The annual incidence of male breast cancer in Japan is less than 5 per million. 8 Jewish men have been shown to have an average incidence of 2.3/100 000 per year, irrespective of living in Israel 9 or the United States. The lowest incidence of both male breast cancer and prostate cancer was among the Japanese, and highest incidence of both male breast cancer and prostate cancer was among African Americans.
Men with breast cancer have been reported to have an increased risk of generalized secondary malignancy. A retrospective registry-based cohort study was conducted at UC Irvine to examine the risk. 10 From 1988 to 2003 in the California Cancer Registry, 1926 men aged 85 years and younger were diagnosed with a first primary breast cancer, and 221 (11.5%) men developed a second primary cancer. Men with breast cancer had a significantly higher risk of second cancer, particularly for a second primary breast cancer, cutaneous melanoma, and stomach cancer, compared with the general population. They reported a general tendency toward higher risks of second malignancies among younger men compared with older men.
Steroid hormones play a role in both male breast cancer and prostate cancer; however, the exact mechanism is complex. Prostate cancer is androgen dependent and androgen responsive, whereas male breast cancer is estrogen-dependent and generally hormonally responsive. Prostate cancer is less common in cirrhotic patients and does not occur in eunuchs, attributable to hyperestrogenism. One study showed a relatively high frequency of male breast cancer and low frequency of prostate cancer in Egypt, attributed to altered estrogen and androgen levels due to liver damage from schistosomiasis. 11 However, although the risk factors appear to be the opposite for these two diseases, an epidemiologic study showed a direct rather than an inverse relationship between the incidence of prostate cancer and breast cancer in populations groups. 12 We sought to consider the potential relationship of these two diseases by evaluation of patients at our institution with the rare diagnosis of male breast cancer.
Methods
A retrospective review was conducted of male breast cancer patients receiving care at our institution from January 1990 through August 2006. Diagnosis codes were screened for the diagnosis of breast cancer in all patients identified as being male gender (ICD-9 175, 1750 or 1759), and pertinent medical records were reviewed. Histopathologic characteristics and hormone receptor expression were obtained. In addition, charts were reviewed for a diagnosis of prostate cancer and for reported prostate-specific antigen (PSA) values.
Results
Of the 69 patients with male breast cancer, 12 were also diagnosed with prostate cancer. In these 12 patients with both breast and prostate cancer, 7 were Caucasian and 5 were African American. Mean age was 78.8 years (range: 66.6-96.0) (mean age at diagnosis for breast cancer was 69.9 years (range: 60.0-83.3). Treatments administered are shown in Table 1 . Eleven of 12 patients underwent mastectomy. Three of 12 patients underwent chemotherapy, and 2 of 12 patients underwent radiation therapy for treatment of breast cancer. In all, 10 of 12 patients had hormonal therapy for breast cancer in the form of tamoxifen. In these 12 patients, 9 had estrogen receptor (ER)-positive status and 3 were unreported. Five had progesterone receptor (PR)-positive status, three had PRnegative status and four were unreported. One had human epidermal growth factor receptor-2 (HER-2)/neu receptor (HR)-positive status, five had HR-negative status and six were unreported.
Of the 12 patients with both breast and prostate cancer, 7 patients had Gleason 6 adenocarcinoma of the prostate, and 5 patients had unreported Gleason grade due to the diagnosis being made outside our institution, and so records were unavailable. In six cases, the breast cancer diagnosis preceded the prostate cancer diagnosis and in six cases, the prostate cancer was prior to the breast cancer. Two of 12 had hormonal ablation for prostate cancer. Two patients had a radical prostatectomy; five underwent radiation therapy for treatment of their prostate cancer and one is under watchful waiting surveillance. Two patients with both male breast cancer and prostate cancer had unknown treatment for prostate cancer. None of these 12 patients were deceased at time of this study; 2 have metastatic breast cancer.
Prostate-specific antigen levels were obtained for 36 of the 69 male breast cancer patients. For the patients without a prior diagnosis of prostate cancer, 9 patients had PSA levels that were 0-1.0 ng per 100 ml. Ten patients had PSA levels that were 1.01-2.5 ng per 100 ml, three patients had PSA levels that were Male breast cancer and prostate cancer UJ Lee and JS Jones 2.51-4.0 ng per 100 ml and five patients had PSA levels that were greater than 4.0 ng per 100 ml. Of the five patients with PSA levels greater than 4.0 ng per 100 ml, one was offered prostate biopsy and chose to follow their PSA, and the remaining four patients with elevated PSA are being followed or lost to follow-up. Twelve patients of the 69 patients with breast cancer have been diagnosed with prostate cancer as described above. Overall, 38 of the 60 male breast cancer patients were screened for prostate cancer. PSA levels were obtained for 36 of the 38 male breast cancer patients, and 2 patients carried a diagnosis of prostate cancer but PSA levels were not available.
Within this cohort of male breast cancer patients, the incidence of other second malignancy is as follows: five patients also had melanoma, three had transitional cell carcinoma of the bladder, two had renal cell carcinoma, one had testicular cancer, one had lung cancer, one had colon cancer, one had basal cell carcinoma and one had squamous cell carcinoma of the skin.
Discussion
Breast cancer is the stereotypical 'women's cancer' and prostate cancer is its stereotypical male counterpart. However, breast cancer overlaps the genders, occurring uncommonly in the vestigial organ in males. Ironically, prostate cancer is the most common solid tumor to metastasize to the breast. 13 Steroid hormones play a role in both male breast cancer and prostate cancer. Prostate cancer is androgen-dependent and androgen responsive, whereas male breast cancer is estrogen dependent and generally hormonally responsive. Estrogen receptors are positive in more than 85% of cases of male breast cancer, and are likely responsible for the good hormonal response. In combination with androgens, estrogens can induce aberrant growth and malignancy of the prostate gland. The treatment of male breast cancer patients with aromatase inhibitors, which is standard therapy for estrogen receptor-positive breast tumors, has been shown to increase testosterone. Aromatase inhibitor therapy is hypothesized to stimulate prostate cancer, but the relationship is hypothetical.
14 Breast cancer risk in men is related to an imbalance of estrogen and testosterone, notably related to factors increasing the amount of circulating estrogens relative to androgens. 15 Men with Klinefelter's syndrome have a 20-50 times increased risk of breast cancer compared with 46XY men, accounting for 3% of male breast cancer cases. 16 Also, men with a history of mumps, orchitis, undescended testes or testicular injury are at increased risk, due to androgen deficiency or excess estrogen. 17 The effects of estrogen are known to predispose patients to male breast cancer, yet these same estrogenic effects are used to treat prostate cancer. There are case reports of men who have developed breast cancer after estrogen treatment of prostate cancer. 18 Studies relating levels of estrogen as well as obesity in male breast cancer patients and matched controls have not been consistent; 19, 20 but, appear to increase risk. Other etiologic factors in male breast cancer include occupational hazards such as chronic heat exposure, which suppresses testicular function. 21 Family history has been shown to be a significant risk factor for both diseases. A family history of breast cancer confers a relative risk of 2.5 and 20% of men with breast cancer have a first-degree relative with the disease. 15 Susceptibility can result from rare mutations in high penetrance genes, such as BRCA1 and BRCA2. 7 The BRCA2 germ-line mutation occurs in 4-40% of male breast cancer patients in published series, 22, 23 and may be a useful marker in identifying men who are at increased risk. Cases of male breast cancer are more common in families with BRCA2 mutation than the BRCA1 mutation. 24 The BRCA2 gene has also been associated with prostate cancer. 25 Studies of families with breast cancer have indicated that male carriers of BRCA2 mutations may be at increased risk of prostate cancer, particularly at an early age. 26 Predisposition to prostate cancer has a genetic component, and there are reports of familial clustering of breast and prostate cancer. Two highly penetrant genes that predispose individuals to breast cancer (BRCA1 and BRCA2) are known to confer an increased risk of prostate cancer of about threefold and sevenfold, respectively, in breast cancer families. Germ-line mutations in BRCA2 may, therefore, account for about 5% of prostate cancer in familial clusters. 27 One recent study demonstrated that the Icelandic BRCA2 999del5 founder mutation was identified in 30 patients (5.7%) of the Icelandic male population-based registry and was strongly associated with rapidly progressing lethal prostate cancer. BRCA2 999del5 mutation carriers had a lower mean age at diagnosis (69.0 years versus 74.0 years; P ¼ 0.002), more advanced tumor stage (stages 3 or 4, 79.3 versus 38.6%; Po0.001), higher tumor grade (grades G3-4, 84.0 versus 52.7%, P ¼ 0.007), shorter median survival time (2.1 years, 95% CI ¼ 1.4-3.6 years, versus 12.4 years, 95% CI ¼ 9.9-19.7 years) and was also associated with an increased risk of dying from prostate cancer. 28 Pathologically, virtually all known histologic types of breast cancer have been identified in men. Infiltrating ductal carcinoma is the most common subtype, comprising 70-90% of cases. 29 Estrogen receptors are positive in more than 85-90% of cases of male breast cancer, 30 and this is likely responsible for the good hormonal response. Progesterone receptors are positive in 92-96% of cases. 31 Other receptors that have been studied, include androgen receptors and glucocorticoid receptors, but their prognostic significance is unknown. The human HER-2/ neu oncogene expression also has potential clinical utility in male breast cancer. Overexpression of this protein on a cancer cell provides information that can guide treatment. Clinical trials show that cancers with overexpression of HER-2/neu are particularly sensitive to a variety of agents. Trastuzumab (Herceptin) is a drug currently in use for HER-2/neu-positive metastatic breast cancer.
Previous studies of male breast cancer has been shown to have a worse prognosis than breast cancer in women, with 5-year mortality from 36-75%. 32 However, more recent data have demonstrated that the prognosis for male breast cancer is similar to female breast cancer, when compared stage for stage. The treatment of male breast cancer patients with aromatase inhibitors, which is standard therapy for estrogen receptor-positive breast tumors, has been shown to increase testosterone, and may stimulate prostate cancer. 32 Aromatase inhibitors
Male breast cancer and prostate cancer UJ Lee and JS Jones (anastrozole, letrozole and exemastane) block the production of small amounts of estrogen by the adrenal glands. Aromatase inhibitors can be used in male breast cancer patients in combination with a GNRH agonist with careful monitoring of PSA and testosterone. The effect of medications in patients with a history of hormonally responsive cancer should be noted. For example, estramustine is a chemotherapy agent used for the palliative treatment of metastatic and/or progressive prostate cancer. It is a derivative of estrogen, and not recommended for use in men with a history of breast cancer. In addition, gynecomastia and breast pain is a bothersome potential side effect in men receiving hormone therapy for prostate cancer, and it has been cited as a contributing reason for premature withdrawal from therapy. Treatment options include prophylactic radiotherapy, tamoxifen use and, in severe cases, surgery may be warranted.
Estrogen induction of cell proliferation is a crucial step in carcinogenesis of gynecologic target tissues, and the mitogenic effects of estrogen in these tissues (such as breast, endometrium and ovary) are well documented both in vitro and in vivo. There is also evidence that prostate (and colon) cancer growth is influenced by estrogens. Estrogen action is mediated through two receptor subtypes: estrogen receptors a (ERa) and b (ERb). In all of these tissues, most studies have shown decreased ERb expression in cancer as compared with benign tumors or normal tissues, whereas ERa expression persists. 33 In combination with androgens, estrogens can induce aberrant growth and malignancy of the prostate gland. ERa plays an essential role in the induction of prostatic squamous metaplasia. 34 Metachronous occurrences of both prostate and breast cancer in male patients are infrequent in the literature. Only 10 of 161 patients evaluated with male breast cancer at Dana-Farber Cancer Institute and Massachusetts General Hospital between 1977 and 2000 were also diagnosed with prostate cancer. Breast cancer preceded prostate cancer in eight of these men. The clinical features and, course of, the breast cancers diagnosed in their series did not appear significantly different from those described for the general population of male breast cancer patients. 35 A Swedish study demonstrated a small increased risk of a second primary cancer following prostate cancer, primarily endocrine-related cancer such as male breast cancer. 36 As a follow-up to this study, the Swedish group examined whether estrogen treatment for prostate cancer and/or family history is responsible for this risk. 37 They performed a nested case-control study in 41 men who had previously been identified with prostate cancer, followed by male breast cancer compared with 81 matched controls with prostate cancer only. They also performed a family study including relatives of men with a diagnosis of prostate as well as breast cancer, irrespective of which was first. Cases with prostate followed by breast cancer received estrogen treatment more often than controls with prostate cancer only. Mean time from prostate cancer diagnosis to breast cancer diagnosis was 47.6 months. In the family study, an increased risk of prostate cancer was found in relatives of men who carried both diagnoses. Two families' pedigree analyses revealed an estimated 100 and 49% probability, respectively, that the proband was a BRCA2 carrier. This study suggests that the increased risk of breast cancer following prostate cancer may be explained by estrogen treatment. However, in a small number of men with prostate as well as breast cancer, pedigree analysis suggests that BRCA2 mutation could be an underlying etiologic factor.
The present study identified a significant risk of prostate cancer in men diagnosed with male breast cancer. Although it is well recognized that the lifetime risk of being diagnosed with prostate cancer is appreciable, the 17% rate in the study period was higher than would be expected in the general population. The incidence rate of prostate cancer is 163.8 per 100 000 in the United States based on data collected from cancer registries participating in NCI's SEER program and CDC's National Program of Cancer Registries 1998-2002. 38 This is unlikely to be due to aggressive screening, because only 38 of the 69 male breast cancer patients had undergone PSA screening, so we believe this represents a true increased risk of prostate cancer in the male breast cancer population. Of 38 male breast cancer patients screened for prostate cancer, 12 were found to have prostate cancer. Therefore, the risk of the screened population is 31.5%, higher than the risk of finding cancer in a typical screening population of 21-30%. In the Tyrol screening study, of 3446 consecutive screening volunteers with a PSA level of 2.0-10.0 ng ml À1 , the prostate cancer detection rate for patients with a PSA value of 2.0-3.9 ng ml À1 (n ¼ 1522, group 1) and 4.0-10.0 ng ml À1 (n ¼ 1924, group 2) was 21% (n ¼ 320) and 30% (n ¼ 572), respectively. 39 Our study is limited by the retrospective nature of the study. In addition, some of our patients received prostate cancer treatment outside our institution, so complete records are unavailable. A relationship between PSA value and prior hormonal therapy could not be established in this limited number of patients. Future prospective studies of the risk of male breast cancer on prostate cancer screening may be warranted.
Conclusion
Male breast cancer patients have at least a 17% incidence of prostate cancer in this cohort, with no trend toward initial diagnosis of one malignancy compared with the other. This risk factor has implications for careful prostate cancer screening.
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